UniProt ID | G3BP1_HUMAN | |
---|---|---|
UniProt AC | Q13283 | |
Protein Name | Ras GTPase-activating protein-binding protein 1 | |
Gene Name | G3BP1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 466 | |
Subcellular Localization | Cytoplasm, cytosol . Perikaryon . Cytoplasm, Stress granule . Nucleus . Cytoplasmic in proliferating cells (PubMed:11604510). Cytosolic and partially nuclear in resting cells (PubMed:11604510). Recruited to stress granules in response to arsenite tre | |
Protein Description | ATP- and magnesium-dependent helicase. [PubMed: 9889278 Unwinds preferentially partial DNA and RNA duplexes having a 17 bp annealed portion and either a hanging 3' tail or hanging tails at both 5'- and 3'-ends] | |
Protein Sequence | MVMEKPSPLLVGREFVRQYYTLLNQAPDMLHRFYGKNSSYVHGGLDSNGKPADAVYGQKEIHRKVMSQNFTNCHTKIRHVDAHATLNDGVVVQVMGLLSNNNQALRRFMQTFVLAPEGSVANKFYVHNDIFRYQDEVFGGFVTEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQAVVSNDMEEHLEEPVAEPEPDPEPEPEQEPVSEIQEEKPEPVLEETAPEDAQKSSSPAPADIAQTVQEDLRTFSWASVTSKNLPPSGAVPVTGIPPHVVKVPASQPRPESKPESQIPPQRPQRDQRVREQRINIPPQRGPRPIREAGEQGDIEPRRMVRHPDSHQLFIGNLPHEVDKSELKDFFQSYGNVVELRINSGGKLPNFGFVVFDDSEPVQKVLSNRPIMFRGEVRLNVEEKKTRAAREGDRRDNRLRGPGGPRGGLGGGMRGPPRGGMVQKPGFGVGRGLAPRQ | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
3 | Sulfoxidation | -----MVMEKPSPLL -----CCCCCCCCCE | 5.45 | 21406390 | |
5 | Ubiquitination | ---MVMEKPSPLLVG ---CCCCCCCCCEEC | 32.47 | 21890473 | |
5 | Ubiquitination | ---MVMEKPSPLLVG ---CCCCCCCCCEEC | 32.47 | - | |
5 | Methylation | ---MVMEKPSPLLVG ---CCCCCCCCCEEC | 32.47 | 23644510 | |
5 | Malonylation | ---MVMEKPSPLLVG ---CCCCCCCCCEEC | 32.47 | 26320211 | |
7 | Phosphorylation | -MVMEKPSPLLVGRE -CCCCCCCCCEECHH | 38.97 | 29255136 | |
19 | Phosphorylation | GREFVRQYYTLLNQA CHHHHHHHHHHHHHC | 6.45 | 28152594 | |
20 | Phosphorylation | REFVRQYYTLLNQAP HHHHHHHHHHHHHCH | 5.20 | 28152594 | |
21 | Phosphorylation | EFVRQYYTLLNQAPD HHHHHHHHHHHHCHH | 21.60 | 28857561 | |
36 | Ubiquitination | MLHRFYGKNSSYVHG HHHHHHCCCCCCCCC | 42.13 | 21890473 | |
36 | Ubiquitination | MLHRFYGKNSSYVHG HHHHHHCCCCCCCCC | 42.13 | 21890473 | |
36 | Acetylation | MLHRFYGKNSSYVHG HHHHHHCCCCCCCCC | 42.13 | 26051181 | |
38 | Phosphorylation | HRFYGKNSSYVHGGL HHHHCCCCCCCCCCC | 26.91 | 28152594 | |
39 | Phosphorylation | RFYGKNSSYVHGGLD HHHCCCCCCCCCCCC | 40.34 | 28152594 | |
40 | Phosphorylation | FYGKNSSYVHGGLDS HHCCCCCCCCCCCCC | 9.04 | 28152594 | |
47 | Phosphorylation | YVHGGLDSNGKPADA CCCCCCCCCCCCCHH | 53.15 | 25849741 | |
50 | Acetylation | GGLDSNGKPADAVYG CCCCCCCCCCHHHCC | 41.08 | 26051181 | |
50 | Ubiquitination | GGLDSNGKPADAVYG CCCCCCCCCCHHHCC | 41.08 | 21890473 | |
50 | Ubiquitination | GGLDSNGKPADAVYG CCCCCCCCCCHHHCC | 41.08 | 21890473 | |
56 | Phosphorylation | GKPADAVYGQKEIHR CCCCHHHCCHHHHHH | 18.63 | 27155012 | |
59 | Ubiquitination | ADAVYGQKEIHRKVM CHHHCCHHHHHHHHH | 55.03 | 21890473 | |
59 | Ubiquitination | ADAVYGQKEIHRKVM CHHHCCHHHHHHHHH | 55.03 | 21890473 | |
59 | Acetylation | ADAVYGQKEIHRKVM CHHHCCHHHHHHHHH | 55.03 | 23236377 | |
64 | Ubiquitination | GQKEIHRKVMSQNFT CHHHHHHHHHHCCCC | 28.29 | - | |
67 | Phosphorylation | EIHRKVMSQNFTNCH HHHHHHHHCCCCCCC | 25.59 | 28857561 | |
71 | Phosphorylation | KVMSQNFTNCHTKIR HHHHCCCCCCCCEEE | 44.48 | - | |
75 | Phosphorylation | QNFTNCHTKIRHVDA CCCCCCCCEEEEEEC | 30.30 | 28857561 | |
76 | Ubiquitination | NFTNCHTKIRHVDAH CCCCCCCEEEEEECC | 17.68 | - | |
76 | Acetylation | NFTNCHTKIRHVDAH CCCCCCCEEEEEECC | 17.68 | 23749302 | |
76 | Malonylation | NFTNCHTKIRHVDAH CCCCCCCEEEEEECC | 17.68 | 26320211 | |
111 | Phosphorylation | ALRRFMQTFVLAPEG HHHHHHHHHHHCCCC | 12.15 | 28857561 | |
119 | Phosphorylation | FVLAPEGSVANKFYV HHHCCCCCHHCEEEE | 19.18 | 28857561 | |
123 | Acetylation | PEGSVANKFYVHNDI CCCCHHCEEEEECCH | 28.47 | 26051181 | |
123 | Ubiquitination | PEGSVANKFYVHNDI CCCCHHCEEEEECCH | 28.47 | - | |
125 | Phosphorylation | GSVANKFYVHNDIFR CCHHCEEEEECCHHH | 11.47 | 28152594 | |
133 | Phosphorylation | VHNDIFRYQDEVFGG EECCHHHCCCCCCCC | 15.01 | 22167270 | |
143 | Phosphorylation | EVFGGFVTEPQEESE CCCCCCCCCCCCCCH | 39.42 | 22167270 | |
149 | Phosphorylation | VTEPQEESEEEVEEP CCCCCCCCHHHCCCH | 49.94 | 19664994 | |
162 | Phosphorylation | EPEERQQTPEVVPDD CHHHHHCCCCCCCCC | 17.06 | 29496963 | |
170 | Phosphorylation | PEVVPDDSGTFYDQA CCCCCCCCCCCCCEE | 47.30 | 26074081 | |
172 | Phosphorylation | VVPDDSGTFYDQAVV CCCCCCCCCCCEECC | 23.99 | 26074081 | |
174 | Phosphorylation | PDDSGTFYDQAVVSN CCCCCCCCCEECCCC | 13.64 | 20068231 | |
180 | Phosphorylation | FYDQAVVSNDMEEHL CCCEECCCCCHHHHH | 22.10 | 20068231 | |
214 | Sumoylation | VSEIQEEKPEPVLEE HHHHHHHCCCCCCCC | 54.66 | - | |
222 | Phosphorylation | PEPVLEETAPEDAQK CCCCCCCCCCHHHHH | 37.83 | 26074081 | |
230 | Phosphorylation | APEDAQKSSSPAPAD CCHHHHHCCCCCCHH | 24.78 | 29255136 | |
231 | Phosphorylation | PEDAQKSSSPAPADI CHHHHHCCCCCCHHH | 47.58 | 29255136 | |
232 | Phosphorylation | EDAQKSSSPAPADIA HHHHHCCCCCCHHHH | 31.97 | 29255136 | |
241 | O-linked_Glycosylation | APADIAQTVQEDLRT CCHHHHHHHHHHHHH | 18.35 | 30059200 | |
241 | Phosphorylation | APADIAQTVQEDLRT CCHHHHHHHHHHHHH | 18.35 | 30266825 | |
247 | Methylation | QTVQEDLRTFSWASV HHHHHHHHHCCCCCC | 46.15 | - | |
248 | Phosphorylation | TVQEDLRTFSWASVT HHHHHHHHCCCCCCC | 29.35 | 20873877 | |
250 | O-linked_Glycosylation | QEDLRTFSWASVTSK HHHHHHCCCCCCCCC | 22.56 | 30059200 | |
250 | Phosphorylation | QEDLRTFSWASVTSK HHHHHHCCCCCCCCC | 22.56 | 25159151 | |
253 | Phosphorylation | LRTFSWASVTSKNLP HHHCCCCCCCCCCCC | 21.48 | 23401153 | |
255 | Phosphorylation | TFSWASVTSKNLPPS HCCCCCCCCCCCCCC | 31.33 | 23898821 | |
256 | O-linked_Glycosylation | FSWASVTSKNLPPSG CCCCCCCCCCCCCCC | 19.86 | 30059200 | |
256 | Phosphorylation | FSWASVTSKNLPPSG CCCCCCCCCCCCCCC | 19.86 | 23898821 | |
257 | Acetylation | SWASVTSKNLPPSGA CCCCCCCCCCCCCCC | 53.81 | 26051181 | |
262 | Phosphorylation | TSKNLPPSGAVPVTG CCCCCCCCCCCCCCC | 37.13 | 28555341 | |
268 | Phosphorylation | PSGAVPVTGIPPHVV CCCCCCCCCCCCCEE | 24.27 | 21082442 | |
268 | O-linked_Glycosylation | PSGAVPVTGIPPHVV CCCCCCCCCCCCCEE | 24.27 | 30059200 | |
280 | Phosphorylation | HVVKVPASQPRPESK CEEEECCCCCCCCCC | 34.35 | 28555341 | |
280 | O-linked_Glycosylation | HVVKVPASQPRPESK CEEEECCCCCCCCCC | 34.35 | 30059200 | |
286 | Phosphorylation | ASQPRPESKPESQIP CCCCCCCCCCHHHCC | 57.08 | 28555341 | |
287 | Ubiquitination | SQPRPESKPESQIPP CCCCCCCCCHHHCCC | 51.66 | - | |
287 | Acetylation | SQPRPESKPESQIPP CCCCCCCCCHHHCCC | 51.66 | 26051181 | |
339 | Phosphorylation | RMVRHPDSHQLFIGN CCCCCCCCCCEEECC | 19.99 | 20873877 | |
353 | Ubiquitination | NLPHEVDKSELKDFF CCCCCCCHHHHHHHH | 51.51 | 19608861 | |
353 | Acetylation | NLPHEVDKSELKDFF CCCCCCCHHHHHHHH | 51.51 | 23236377 | |
354 | Phosphorylation | LPHEVDKSELKDFFQ CCCCCCHHHHHHHHH | 43.63 | 28555341 | |
357 | Ubiquitination | EVDKSELKDFFQSYG CCCHHHHHHHHHHHC | 48.73 | - | |
362 | Phosphorylation | ELKDFFQSYGNVVEL HHHHHHHHHCCEEEE | 29.83 | 28796482 | |
363 | Phosphorylation | LKDFFQSYGNVVELR HHHHHHHHCCEEEEE | 11.26 | 28796482 | |
373 | Phosphorylation | VVELRINSGGKLPNF EEEEEECCCCCCCCE | 46.69 | 22617229 | |
376 | Acetylation | LRINSGGKLPNFGFV EEECCCCCCCCEEEE | 65.38 | 19608861 | |
376 | Sumoylation | LRINSGGKLPNFGFV EEECCCCCCCCEEEE | 65.38 | 28112733 | |
376 | Ubiquitination | LRINSGGKLPNFGFV EEECCCCCCCCEEEE | 65.38 | 19608861 | |
388 | Phosphorylation | GFVVFDDSEPVQKVL EEEEECCCHHHHHHH | 45.72 | 21406692 | |
393 | Ubiquitination | DDSEPVQKVLSNRPI CCCHHHHHHHHCCCE | 45.43 | - | |
403 | Methylation | SNRPIMFRGEVRLNV HCCCEEEEEEEEECH | 24.00 | - | |
413 | Acetylation | VRLNVEEKKTRAARE EEECHHHHHHHHHHH | 46.03 | 25953088 | |
427 | Methylation | EGDRRDNRLRGPGGP HCCCCCCCCCCCCCC | 30.01 | - | |
429 | Asymmetric dimethylarginine | DRRDNRLRGPGGPRG CCCCCCCCCCCCCCC | 46.12 | - | |
429 | Methylation | DRRDNRLRGPGGPRG CCCCCCCCCCCCCCC | 46.12 | 24129315 | |
435 | Methylation | LRGPGGPRGGLGGGM CCCCCCCCCCCCCCC | 55.90 | 24129315 | |
435 | Asymmetric dimethylarginine | LRGPGGPRGGLGGGM CCCCCCCCCCCCCCC | 55.90 | - | |
443 | Methylation | GGLGGGMRGPPRGGM CCCCCCCCCCCCCCC | 58.71 | - | |
447 | Methylation | GGMRGPPRGGMVQKP CCCCCCCCCCCCCCC | 58.39 | 24129315 | |
447 | Dimethylation | GGMRGPPRGGMVQKP CCCCCCCCCCCCCCC | 58.39 | - | |
453 | Methylation | PRGGMVQKPGFGVGR CCCCCCCCCCCCCCC | 35.38 | - | |
460 | Methylation | KPGFGVGRGLAPRQ- CCCCCCCCCCCCCC- | 34.25 | 24129315 | |
460 | Dimethylation | KPGFGVGRGLAPRQ- CCCCCCCCCCCCCC- | 34.25 | - | |
465 | Methylation | VGRGLAPRQ------ CCCCCCCCC------ | 49.59 | 24129315 | |
465 | Dimethylation | VGRGLAPRQ------ CCCCCCCCC------ | 49.59 | - |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of G3BP1_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-376, AND MASS SPECTROMETRY. | |
Methylation | |
Reference | PubMed |
"Identifying and quantifying in vivo methylation sites by heavy methylSILAC."; Ong S.E., Mittler G., Mann M.; Nat. Methods 1:119-126(2004). Cited for: METHYLATION [LARGE SCALE ANALYSIS] AT ARG-435; ARG-447; ARG-460 ANDARG-465, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149 AND SER-232, ANDMASS SPECTROMETRY. | |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230 AND SER-232, ANDMASS SPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149; SER-231 ANDSER-232, AND MASS SPECTROMETRY. | |
"Large-scale phosphoproteome analysis of human liver tissue byenrichment and fractionation of phosphopeptides with strong anionexchange chromatography."; Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,Zou H., Gu J.; Proteomics 8:1346-1361(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149, AND MASSSPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-143; SER-149; SER-232AND SER-373, AND MASS SPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149 AND SER-232, ANDMASS SPECTROMETRY. | |
"Combining protein-based IMAC, peptide-based IMAC, and MudPIT forefficient phosphoproteomic analysis."; Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,Yates J.R. III; J. Proteome Res. 7:1346-1351(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149 AND SER-232, ANDMASS SPECTROMETRY. | |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-231 AND SER-232, ANDMASS SPECTROMETRY. | |
"Global proteomic profiling of phosphopeptides using electron transferdissociation tandem mass spectrometry."; Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230; SER-231 ANDSER-232, AND MASS SPECTROMETRY. | |
"Quantitative phosphoproteome profiling of Wnt3a-mediated signalingnetwork: indicating the involvement of ribonucleoside-diphosphatereductase M2 subunit phosphorylation at residue serine 20 in canonicalWnt signal transduction."; Tang L.-Y., Deng N., Wang L.-S., Dai J., Wang Z.-L., Jiang X.-S.,Li S.-J., Li L., Sheng Q.-H., Wu D.-Q., Li L., Zeng R.; Mol. Cell. Proteomics 6:1952-1967(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149, AND MASSSPECTROMETRY. | |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND MASSSPECTROMETRY. | |
"Toward a global characterization of the phosphoproteome in prostatecancer cells: identification of phosphoproteins in the LNCaP cellline."; Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.; Electrophoresis 28:2027-2034(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND MASSSPECTROMETRY. | |
"Phosphoproteome analysis of the human mitotic spindle."; Nousiainen M., Sillje H.H.W., Sauer G., Nigg E.A., Koerner R.; Proc. Natl. Acad. Sci. U.S.A. 103:5391-5396(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-149, AND MASSSPECTROMETRY. | |
"Quantitative phosphoproteome analysis using a dendrimer conjugationchemistry and tandem mass spectrometry."; Tao W.A., Wollscheid B., O'Brien R., Eng J.K., Li X.-J.,Bodenmiller B., Watts J.D., Hood L., Aebersold R.; Nat. Methods 2:591-598(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND MASSSPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-232, AND MASSSPECTROMETRY. | |
"RasGAP-associated endoribonuclease G3Bp: selective RNA degradationand phosphorylation-dependent localization."; Tourriere H., Gallouzi I.-E., Chebli K., Capony J.-P., Mouaikel J.,van der Geer P., Tazi J.; Mol. Cell. Biol. 21:7747-7760(2001). Cited for: FUNCTION AS AN ENDORIBONUCLEASE, PHOSPHORYLATION AT SER-149 ANDSER-232, AND MUTAGENESIS OF SER-149 AND SER-232. |